ALPMY: Astellas Pharma insider trading, 5% holders and institutional ownership
From public SEC filings: open-market insider purchases and sales (Form 4, last 180 days), holders of 5% or more (Schedules 13D and 13G) and institutional ownership (Form 13F). Insider and 5% data delayed 48 hours.
Insider trading
0 open-market buys totaling - and 0 sales totaling - in the last 180 days.
Institutional ownership (Q2 2026)
7 institutions reported holding $518K of Astellas Pharma on Form 13F (7 the quarter before). 1 opened a new position and 1 sold out. Shares held by institutions: -54%.
| Largest holders | Shares | Value |
|---|---|---|
| RHUMBLINE ADVISERS | 21,642 | $289K |
| GAMMA Investing LLC | 12,434 | $166K |
| WELLINGTON-ALTUS USA INC. | 2,017 | $32K |
| First Command Advisory Services, Inc. | 1,278 | $17K |
| Salomon & Ludwin, LLC | 734 | $10K |
| HANTZ FINANCIAL SERVICES, INC. | 189 | $3K |
| PNC Financial Services Group, Inc. | 70 | $936 |
Clinical trial readouts
5 Phase 2 or 3 trials by Astellas Pharma with a primary completion date in the last 90 days or the next 12 months and no results posted yet, from ClinicalTrials.gov. (est.) = company estimate.
| Primary completion | Drug | Condition | Phase | Patients | Status | Trial |
|---|---|---|---|---|---|---|
| 2026-10-31 (est.) | zolbetuximab | Pancreatic Cancer | Phase 2 | 393 | Enrollment complete | NCT03816163 |
| 2026-12-30 (est.) | XNW27011 | Pancreatic Adenocarcinoma Metastatic | Phase 1/2 | 240 | Enrollment complete | NCT06792435 |
| 2027-06-30 (est.) | zolbetuximab | Pharmacokinetics of Zolbetuximab | Phase 2 | 143 | Enrollment complete | NCT03505320 |
| 2027-10-30 (est.) | Roxadustat | Chronic Kidney Disease | Phase 3 | 98 | Enrollment complete | NCT05970172 |
| 2027-10-31 (est.) | ASP2957 | X-Linked Myotubular Myopathy | Phase 1/2 | 9 | Recruiting | NCT07052929 |
Get new insider and activist filings the morning after: daily alerts. Not investment advice.